| Literature DB >> 3164697 |
M E van der Burg1, F B Lammes, W L van Putten, G Stoter.
Abstract
Eighty-five patients with epithelial ovarian cancer were studied to assess the prognostic value of the prechemotherapy serum concentration of CA125 and its half-life during induction therapy. The endpoints of the analysis were progression rate and time to progression. The prechemotherapy CA125 level had no prognostic value (P = 0.36) if the patients were stratified for tumor size. The half-life of CA125, however, was an independent prognostic variable (P = 0.01). Patients with a half-life of 20 days and more had a 3.2 times higher progression rate and a significantly shorter median time to progression of only 11 months, as compared to 43 months for patients with a half-life of less than 20 days.Entities:
Mesh：
Substances：
Year: 1988 PMID： 3164697 DOI： 10.1016/0090-8258(88)90244-2
Source DB: PubMed Journal: Gynecol Oncol ISSN： 0090-8258 Impact factor: 5.482